Welcome to our dedicated page for Solid Bioscience news (Ticker: SLDB), a resource for investors and traders seeking the latest updates and insights on Solid Bioscience stock.
Solid Biosciences Inc. (SLDB) is a precision genetic medicine company whose news flow centers on the development of gene therapy candidates for rare neuromuscular and cardiac diseases. Company announcements highlight progress across multiple clinical programs, regulatory designations and collaborations related to its investigational therapies and platform technologies.
Investors and observers following SLDB news can expect updates on key clinical trials such as INSPIRE DUCHENNE and IMPACT DUCHENNE for SGT-003 in Duchenne muscular dystrophy, the FALCON Phase 1b trial of SGT-212 in Friedreich’s ataxia, and the ARTEMIS Phase 1b trial of SGT-501 for catecholaminergic polymorphic ventricular tachycardia. News items also describe interim clinical data, including safety, tolerability, biomarker changes and cardiac monitoring findings, as well as regulatory interactions and designations from agencies such as the U.S. Food and Drug Administration and U.K. authorities.
Solid Biosciences’ news releases additionally cover its proprietary AAV-SLB101 capsid platform, including data presentations at scientific meetings and licensing agreements with partners such as Andelyn Biosciences. Corporate updates, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in industry conferences like the J.P. Morgan Healthcare Conference also appear in the company’s news record.
This news page aggregates these disclosures so readers can review clinical milestones, regulatory developments, platform collaborations and corporate events related to Solid Biosciences and its SLDB stock over time.
Solid Biosciences (Nasdaq: SLDB) dosed the first participant in its multi-country, randomized, placebo-controlled Phase 3 IMPACT DUCHENNE trial of SGT-003 on May 7, 2026. The program complements the Phase 1/2 INSPIRE trial where 46 participants have received SGT-003 and it has been generally well tolerated as of a May 4, 2026 cutoff.
The company received a positive EMA PIP opinion for pediatric development, holds FDA Fast Track, Rare Pediatric and Orphan Drug designations, and was awarded a UK Innovation Passport under ILAP.
Solid Biosciences (Nasdaq: SLDB) granted 8,070 restricted stock units (RSUs) to a newly hired employee on May 1, 2026 as an inducement under Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual installments through the fourth anniversary, subject to continued service, under the 2024 Inducement Stock Incentive Plan.
Solid Biosciences (Nasdaq: SLDB) will present its largest scientific program at the 29th ASGCT Annual Meeting in Boston, May 11–15, 2026. The company will deliver 16 presentations (5 oral, 11 posters) covering clinical updates, next-generation delivery, capsid engineering and scalable AAV manufacturing.
Solid Biosciences (Nasdaq: SLDB) announced the European Commission has granted Orphan Drug designation to SGT-003 for Duchenne muscular dystrophy on April 28, 2026. The designation follows EMA positive opinion and complements the U.K. ILAP Innovation Passport and prior U.S. Fast Track, Orphan Drug, and Rare Pediatric Disease designations.
SGT-003 is in two ongoing trials: the Phase 1/2 INSPIRE DUCHENNE study and the Phase 3 randomized IMPACT DUCHENNE trial as part of a coordinated multinational development plan.
Solid Biosciences (Nasdaq: SLDB) will participate in investor conferences in April 2026. President and CEO Bo Cumbo will join a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026 at 2:15 pm ET.
Management will hold one-on-one meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026. A live webcast of the April 14 presentation will be available on the company’s Investors Events page, with the replay archived for 90 days.
Solid Biosciences (Nasdaq: SLDB) reported Q4 and full-year 2025 results and clinical progress on March 19, 2026. Key updates: SGT-003 showed positive interim Phase 1/2 INSPIRE data in 41 dosed participants and Phase 3 IMPACT dosing expected in April 2026. SGT-212 and SGT-501 advanced into Phase 1b studies. Financials: $187.9M cash at 12/31/25; completed a $240M private placement in March 2026, extending runway into H1 2028; 2025 net loss $174.3M and R&D $140.3M.
Solid Biosciences (NASDAQ: SLDB) reported interim positive Phase 1/2 INSPIRE DUCHENNE results for SGT-003 on March 11, 2026, with 40 participants dosed as of that date. Data show robust microdystrophin expression, restoration of DAPC components (beta-sarcoglycan, nNOS), biomarker improvements, and stabilization-to-improvement in LVEF; safety remained generally favorable. The company plans additional FDA meetings in H1 2026 to discuss a potential accelerated approval pathway and will provide a mid-2026 update.
Solid Biosciences (Nasdaq: SLDB) entered a securities purchase agreement for an approximately $240 million private placement, expected to close on or about March 9, 2026, subject to customary closing conditions. The financing sells 14,973,257 common shares at $5.61 and offers pre-funded warrants for up to 27,807,482 shares at $5.609 each.
Proceeds are planned for pipeline development, business development, working capital, and general corporate purposes. The company will file a resale registration statement with the SEC within 30 days after closing. Joint lead placement agents include Leerink Partners and Citigroup.
Solid Biosciences (Nasdaq: SLDB) will present clinical and preclinical data at the 2026 MDA Clinical & Scientific Conference in Orlando, March 8-11, 2026. Key highlights include an oral update on the INSPIRE DUCHENNE Phase 1/2 study of SGT-003 (March 11, 1:00 p.m. ET) and multiple posters on March 10 covering SGT-003 capsid design, safety, cardiac tropism, DAPC stabilization, and the SGT-212 AAV FXN program for Friedreich’s ataxia.
Presentations will be posted afterward on the company’s Scientific Publications & Presentations page.
Solid Biosciences (Nasdaq: SLDB) granted 17,600 restricted stock units (RSUs) to one newly hired employee on March 2, 2026. The RSUs vest in four equal annual installments on each one-year anniversary through the fourth anniversary and are subject to continued service.
The award was made under the company’s 2024 Inducement Stock Incentive Plan as an inducement in accordance with Nasdaq Listing Rule 5635(c)(4).